B Lineage Acute Lymphoblastic Leukemia with concurrent IGH and EPOR rearrangements – An Entity with Dismal Outcome

Nupur Pradhan, Prabhjot Kaur, Venus Thakur, Anshu Anshu, Shailja Rathore, Praveen Sharma, Nabhajit Mallik, Man Updesh Singh Sachdeva, Mirza Saleem Amjad, Reena Das, Arihant Jain, Alka Khadwal, Sreejesh Sreedharanunni
{"title":"B Lineage Acute Lymphoblastic Leukemia with concurrent IGH and EPOR rearrangements – An Entity with Dismal Outcome","authors":"Nupur Pradhan, Prabhjot Kaur, Venus Thakur, Anshu Anshu, Shailja Rathore, Praveen Sharma, Nabhajit Mallik, Man Updesh Singh Sachdeva, Mirza Saleem Amjad, Reena Das, Arihant Jain, Alka Khadwal, Sreejesh Sreedharanunni","doi":"10.1007/s12288-024-01818-7","DOIUrl":null,"url":null,"abstract":"<p>The <i>EPOR</i> rearrangement, an uncommon cytogenetic abnormality linked to <i>BCR::ABL1</i>-like B-ALL, is often underdiagnosed due to the absence of a robust testing strategy, especially in resource-constrained settings. We report six cases of B-ALL with concurrent <i>IGH</i> and <i>EPOR</i> rearrangement from India, representing 1.3% of the tested cases, and reviewed the existing literature. The age ranged from 13 to 37 years (median 17 years), with a 2:1 male dominance. Leukocytosis was observed in 67% of patients (median total leukocyte count-105.9 × 10^9/L), and CD20 expression was seen in 67%. One patient experienced induction failure, while three relapsed within a year of diagnosis and treatment. All six patients died within 6 to 21 months of follow-up. These findings align with previous reports of treatment resistance, frequent relapses, and the need for novel therapeutic agents like <i>JAK</i> inhibitors and CART therapy. In summary, these six B-ALL cases with <i>IGH</i> and <i>EPOR</i> rearrangements highlight the diagnostic challenges and poor outcomes associated with this condition.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-024-01818-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The EPOR rearrangement, an uncommon cytogenetic abnormality linked to BCR::ABL1-like B-ALL, is often underdiagnosed due to the absence of a robust testing strategy, especially in resource-constrained settings. We report six cases of B-ALL with concurrent IGH and EPOR rearrangement from India, representing 1.3% of the tested cases, and reviewed the existing literature. The age ranged from 13 to 37 years (median 17 years), with a 2:1 male dominance. Leukocytosis was observed in 67% of patients (median total leukocyte count-105.9 × 10^9/L), and CD20 expression was seen in 67%. One patient experienced induction failure, while three relapsed within a year of diagnosis and treatment. All six patients died within 6 to 21 months of follow-up. These findings align with previous reports of treatment resistance, frequent relapses, and the need for novel therapeutic agents like JAK inhibitors and CART therapy. In summary, these six B-ALL cases with IGH and EPOR rearrangements highlight the diagnostic challenges and poor outcomes associated with this condition.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
并发 IGH 和 EPOR 重排的 B 系急性淋巴细胞白血病--一种预后不佳的病例
EPOR重排是与BCR::ABL1样B-ALL相关的一种不常见的细胞遗传学异常,由于缺乏强有力的检测策略,EPOR往往诊断不足,尤其是在资源有限的环境中。我们报告了来自印度的六例同时伴有IGH和EPOR重排的B-ALL病例,占检测病例的1.3%,并回顾了现有文献。患者年龄从13岁到37岁不等(中位数为17岁),男性占2:1。67%的患者出现白细胞增多(白细胞总数中位数为 105.9 × 10^9/L),67%的患者出现 CD20 表达。一名患者诱导失败,三名患者在诊断和治疗后一年内复发。所有六名患者均在随访的 6 至 21 个月内死亡。这些发现与之前关于耐药性、频繁复发以及需要新型治疗药物(如JAK抑制剂和CART疗法)的报道一致。总之,这六例伴有IGH和EPOR重排的B-ALL病例凸显了与这种疾病相关的诊断难题和不良预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
82
期刊介绍: Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.
期刊最新文献
Can Health Literacy Effectively Enhance Blood Donation Rates? Assessment of Cardiac, Hepatic and Pancreatic Iron Overload in Transfusion Dependent Thalassemia Patients Using T2* Magnetic Resonance Imaging Frameshift Mutation in the EPB41 Gene with Hereditary Elliptocytosis Through the Eyes of the Recipient: Navigating Transfusion Services Amidst COVID-19 in Multi-Transfused Thalassaemic Patients An In-Depth Analysis of Variable Dynamics Influencing Bone Mineral Density in Transfusion-Dependent Thalassemia Patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1